您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Dapagliflozin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Dapagliflozin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Dapagliflozin图片
CAS NO:461432-26-8
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
5mg电议
25mg电议
100mg电议

产品介绍

化学性质

Physical AppearanceA yellow oil
StorageStore at -20°C
M.Wt408.87
Cas No.461432-26-8
FormulaC21H25ClO6
Solubilityinsoluble in H2O; ≥116.6 mg/mL in EtOH; ≥15.1 mg/mL in DMSO
Chemical Name(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Canonical SMILESCCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

hSGLT2的EC50值:1.1±0.06 nM

SGLT2的选择性抑制作用能防止肾对糖再吸收的过程以及促进葡萄糖经尿液排出,已被提出用于帮助糖尿病患者恢复正常的血浆葡萄糖水平。Dapagliflozin是一种有效的和选择性的肾钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂。

体外:Dapagliflozin对hSGLT2和hSGLT1的EC50值分别为1.1 nM和1.4 μM,对SGLT2比对SGLT1的选择性高1200倍,而Phlorizin对两者的选择性只有10倍。Dapagliflozin对大鼠SGLT(rSGLT)2和hSGLT2的抑制能力相当,但Dapagliflozin对rSGLT2的选择性比对rSGLT1的降低至200倍[1]。

体内:对于体内实验,给予大鼠0.1 ~ 1.0 mg/kg的单次口服剂量后,Dapagliflozin显著引起糖尿病和正常大鼠的肾葡萄糖排泄,改善正常大鼠的葡萄糖耐受性以及缓解Zucker糖尿病肥胖大鼠的高血糖[2]。

临床试验:Dapagliflozin以1、2.5和5 mg/天的剂量可有效地减少未经治疗II型糖尿病患者的血糖水平和体重。Dapagliflozin的耐受性良好[3]。

参考文献:
[1] Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN.  Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008 Mar 13; 51(5):1145-9.
[2] Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM.  Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008 Jun; 57(6):1723-9.
[3] Bailey CJ, Iqbal N, T'joen C, List JF.  Dapagliflozin monotherapy in drug-nave patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012 Oct; 14(10):951-9.

试验操作

Cell experiment:[1]

Cell lines

Chinese hamster ovary cells stably expressing human SGLT2 and SGLT1

Reaction Conditions

1.1 nM (EC50)

Applications

Dapagliflozin inhibited accumulation of radiolabeled α-methyl-D-glucopyranoside, with EC50 values of 1.1 nM for human SGLT2 (hSGLT2) and 1.4 μM for hSGLT1.

Animal experiment:[1]

Animal models

Sprague-Dawley rats

Dosage form

0.1, 1.0, and 10 mg/kg

Administered orally

Applications

In normal rats, a single oral dose of 0.1, 1.0, and 10 mg/kg of dapagliflozin induced respective losses of 550, 1100, and 1900 mg of glucose per 200 g of body weight over 24 h. In streptozotocin-induced diabetic rats, a single oral dose of 0.1 mg/kg of dapagliflozin resulted in a 55% reduction in blood glucose level. The above correlation of SGLT2 inhibition, glucosuria, and blood glucose-lowering effects suggest that selective SGLT2 inhibition by dapagliflozin holds promise as a viable approach to treat type 2 diabetes.

Note

The technical data provided above is for reference only.

References:

1. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry, 2008, 51(5): 1145-1149.

生物活性

描述Dapagliflozin是一种有效的和选择性的hSGLT2抑制剂,EC50值为1.1 nM,比对hSGLT1的选择性高1200倍。
靶点hSGLT2     
IC501.1 nM (EC50)